CNR1 and neurodegenerative disease: ECS alterations in neurological disorders include changes in CB1 and/or CB2 receptor expression and endocannabinoid levels, but their impact the onset and progression of the disease remains unclear due to the complexity of the endocannabinoid signaling and the pathophysiology of neurodegenerative diseases.